Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-29
2005-11-29
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S470000, C514S212010, C514S227800, C514S231500, C514S252130, C514S256000, C514S317000, C514S336000, C514S422000, C549S463000, C549S467000, C549S469000, C544S062000, C544S111000, C544S333000, C544S359000, C546S192000, C546S268100, C540S596000, C548S517000
Reexamination Certificate
active
06969730
ABSTRACT:
Compounds of formula (I)or a pharmaceutically acceptable salts or prodrug thereof which are useful for the modulation of the histamine-3 receptors in mammals and which are useful for the treatment of disorders ameliorated by histamine-3 receptor ligands.
REFERENCES:
patent: 3903092 (1975-09-01), Chapman et al.
patent: 3910955 (1975-10-01), Chapman et al.
patent: 4237144 (1980-12-01), Cragoe et al.
patent: 4297369 (1981-10-01), Takizawa et al.
patent: 4447620 (1984-05-01), Sih et al.
patent: 4452986 (1984-06-01), Johnson et al.
patent: 4495357 (1985-01-01), Johnson
patent: 5436246 (1995-07-01), Bernotas et al.
patent: 5648372 (1997-07-01), Naito et al.
patent: 5747508 (1998-05-01), Richter et al.
patent: 5858995 (1999-01-01), Kawai et al.
patent: 6302837 (2001-10-01), De Nanteuil et al.
patent: 0 169 012 (1986-01-01), None
patent: 0 512 570 (1995-10-01), None
patent: 0 978 512 (2000-02-01), None
patent: 0 982 300 (2000-03-01), None
patent: 94/26738 (1994-11-01), None
patent: 95/04052 (1995-02-01), None
patent: 95/29907 (1995-11-01), None
patent: 96/11192 (1996-04-01), None
patent: 98/38188 (1998-09-01), None
patent: 98/52946 (1998-11-01), None
patent: 99/61435 (1999-12-01), None
patent: 00/06254 (2000-02-01), None
patent: 01/23380 (2001-04-01), None
patent: 02/10156 (2002-02-01), None
Repka-Ramirez Curr. Allergy. Asthma Rep. 3(3): 227-31, 2003.
Barocelli et al. Pharmacol. Res. 47(4): 299-304, 2003.
Leurs, R., et al. “Therapeutic potential of histamine H3receptor agonists”, Trends in Pharmacological Sciences 1998, vol. 19 (5), pp.177-183 (May 1998).
Haas, H., et al. “Subcortical modulation of synaptic plasticity in the hippocampus”, Behavioural Brain Research, Germany, vol. 66, pp. 41-44 (Jan. 1995).
Schwartz, J., et al. “Histaminergic transmission in the mammalian brain”, Physiological Reviews, France, vol. 71, No. 1, pp. 1-51 (Jan. 1991).
Descamps et al., “Benzofurans. XLII. Synthesis of 2-benzofurylmethylamines and amides of coumarilic acids,” Chimica therapeutica 5(3):169-184 (1970).
JP 07173158 Abstracts.
Bjenning et al., “Peripherally Administered Ciproxifan Elevates Hypothalamic Histamine Levels And Potently Reduces Food Intake in the Sprague Dawley Rat,” Histamine Research In The New Mellennium, Proceedings Of The International Sendai Histamine Symposium Held In Sendai, Japan, Nov. 22-25, 2000, p. 449-450.
De Almeida et al., “Memory Facilitation by Histamine,” Arch. Int. Pharmacodyn., 283:193-198 (1986).
Delaunois et al., “Modulation Of Acetylcholine, Capsaicin and Substance P Effects by Histamine H3Receptors in ISolated Perfused Rabbit Lungs,” European Journal Of Pharmacology, 277:243-250 (1995).
Dimitriadou et al., “Functional Relationship Between Mast Cells and C-Sensitive Nerve Fibres Evidenced by Histamine H3-Receptor Modulation in Rat Lung and Spleen,” Clinical Science, 87:151-163 (1994).
Duméry et al., “Development of Amygdaloid Cholinergic Mediation of Passive Avoidance Learning in the Rat,” Exp. Brain Res., 67:61-69 (1987).
Ellingboe et al., “Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole 2-Oxides,” J. Med. Chem. 36:2485-2493 (1993).
Fitzsimons et al., “Histamine Receptors Signalling in Epidermal Tumor Cell Lines with H-rasGene Alterations,” Inflamm. Res., 47, Supplement I , S50-S51 (1998).
Haas et al., Subcortical Modulation of Synaptic Plasticity in the Hippocampus, Behavioural Brain Research, 66:41-44 (1995).
Hatta et al., “Activation of Histamine H3Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia1.2,” The Journal of Pharmacology And Experiemental Therapeutics, 283(2):494-500 (19997).
Imamura et al., “Activation Of Histamine H3-Receptors Inhibits Carrier-Mediated Norepinephrine Release During Protracted Myocardial Ischemia,” Circulation Research, 78(3):475-481 (1996).
Imamura et al., “Histamine H3-Receptor-Mediated Inhibition Of Calcitonin Gene-Related Peptide Release From Cardiac C Fiber,” Circulation Research, 78(5):863-869 (1996).
Kamei et al., “Participation Of Histamine In The Step-Through Active Avoidance Response And Its Inhibition By H1-Blockers,” Japan J. Pharmacol., 57:473-482 (1991).
Leurs et al., “The Histamine H3-Receptor: A Target For Developing New Drugs,” Progress In Drug Reseach, 39:127-165 (1992).
Leurs et al., “The Medicinal Chemistry And Therapeutic Potentials Of Ligands Of The Histamine H3Receptor,” Progress In Drug Research, 45:107-165 (1995).
Leurs et al., “Therapeutic Potential Of Histamine H3Receptor Agonists And Antagonists,” Trends In Pharm. Sci, 19:177-183 (1998).
Levi et al., “Histamine H3-Receptors: A New Frontier In Myocardial Ischemia,” The Journal Of Pharmacology And Experimental Therapeutics, 292(3):825-830 (2000).
Lin et al., “Involvement Of Histaminergic Neurons In Arousal Mechanisms Demonstrated With H3-Receptor Ligands In The Cat,” Brain Research, 523:325-330 (1990).
Matsubara et al., “UK-14,304, R(-)α-Methyl-Histamine And SMS 201-995 Block Plasma Protein Leakage Within Dura Mater By Prejunctional Mechanisms,” European Journal Of Pharmacology, 224:145-150 (1992).
Mazurkewicz-Kwilecki et al., “Changes In The Regional Brain Histamine And Histidine Levels In Postmortem Brains Of Alzheimer Patients,” Can. J. Physiol. Pharmacol. 67:75-78 (1989).
McLeod et al., “Histamine H3Antagonists,” Progress In Resp. Research 31:133-134 (2001).
Monti et al., “Effects Of Selective Activation Or Blockade Of The Histamine H3Receptor On Sleep and Wakefulness,” European Journal Of Pharmacolgy, 205:283-287 (1991).
Monti et al., “Sleep and Waking During Acute Histamine H3Agonist BP2.94 Of H3Antagonist Carboperamide (MR 16155) Administration In Rats,” Neuropsychopharmacology, 15(1):31-35 (1996).
Murakami et al., “AQ-0145, A Newly Developed Histamine H3Antagonist, Decreased Seizure Susceptibility OF Electrically Induced Convulsions In Mice,” Meth. Find. Exp. Clin. Pharmacol. 17(C):70-73 (1995).
Onodera et al., “Neuropharmacology Of The Histaminergic Neuron System In The Brain And Its Relationship With Behavioral Disorders,” Progress In Neurobiology 42:685-702 (1994).
Panula et al., “Histamine Neurons in Human Hypothalamus: Anatomy in Normal and Alzheimer Diseased Brains, ” Neuroscience 44(2):465-481 (1991).
Panula et al., “Neuronal Histamine Deficit in Alzheimer's Disease,” Neuroscience 82(4):993-997 (1998).
Perez-Garcia et al., “Effects Of Histamine H3Receptor Ligands in Experimental Models Of Anxiety And Depression,” Psychopharmacology 142:215-220 (1999).
Philips et al., “Recent Advances In Histamine H3Receptor Agents,” Annual Reports In Medicinal Chemistry, 33:31-40 (1998).
Rouleau, “Bioavailability, Antinociceptive And Antiiflammatory Properties Of BP 2-94, A Histamine H3Receptor Agonist Prodrug,” The Journal Of Pharmacology And Experimental Therapeutics, 281(3):1085-1094 (1997).
Sakai et al., “Effects Of Thioperamide, A Histamine H3Receptor Anatagonist, On Locomotor Activity And Brain Histamine Content In Mast Cell-DeficientW/WvMice,” Life Sciences, 48:2397-2404 (1991).
Schwartz et al., “Histaminergic Transmission in the Mammalian Brain,” Physiological Reviews 71(1):1-51 (1991).
Schwartz et al., “Histamine,” Psychopharmacology: The Fourth Generation Of Progress, 397-405 (1995).
Shaywitz et al., “Dopaminergic But Not Noradrenergic Mediation Of Hyperactivity And Performance Deficits In The Developing Rat Pup,” Psychopharmacology, 82:73-77 (1984).
Szelag, “Role Of Histamine H3-Receptors In The Proliferation Of Neoplastic Cells In Vitro,” Med. Sci. Monit., 4(5):747-755 (1998).
Tedford et al., “Cognition And Locomotor Activity In The
Bennani Youssef L.
Black Lawrence A.
Cowart Marlon D.
Faghih Ramin
Gfesser Gregory A.
Abbott Laboratories
Balasubramanian Venkataraman
Chen Portia
LandOfFree
Amines as histamine-3 receptor ligands and their therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amines as histamine-3 receptor ligands and their therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amines as histamine-3 receptor ligands and their therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3517810